Abstract:A bstract Among virtual screening methods that have been developed to facilitate the drug discovery process, chemogenomics presents the particularity to tackle the question of predicting ligands for proteins, at at scales both in the protein and chemical spaces. Therefore, in addition to to predict drug candidates for a given therapeutic protein target, like more classical ligand-based or receptor-based methods do, chemogenomics can also predict off-targets at the proteome level, and therefore, identify potential side-effects or drug repositioning opportunities. In this study, we study and compare machine-learning and deep learning approaches for chemogenomics, that are applicable to screen large sets of compounds against large sets of druggable proteins. State-of-the-art drug chemogenomics methods rely on expert-based chemical and protein descriptors or similarity measures. The recent development of deep learning approaches enabled to design algorithms that learn numerical abstract representations of molecular graphs and protein sequences in an end-to-end fashion, i.e., so that the learnt features optimise the objective function of the drug-target interaction prediction task. In this paper, we address drug-target interaction prediction at the druggable proteome-level, with what we define as the chemogenomic neuron network. This network consists of a feed-forward neuron network taking as input the combination of molecular and protein representations learnt by molecular graph and protein sequence encoders. We first propose a standard formulation of this chemogenomic neuron network. Then, we compare the performances of the standard chemogenomic network to reference deep learning or shallow (machine-learning without deep learning) methods. In particular, we show that such a representation learning approach is competitive with state-of-the-art chemogenomics with shallow methods, but not ultimately superior. We evaluate the most promising neuron network architectures and data augmentation techniques, such as multi-view and transfer learning, to improve the prediction performance of the chemogenomic network. Our results shed new insights on the design of chemogenomics approaches based on representation learning algorithms. Most importantly, we conclude from our observations that a promising research direction is to integrate heterogeneous sources of data such as various bioactivity datasets, or independently, multiple molecule and protein attribute views, instead of focusing on sophisticated, yet intuitively relevant, encoder’s neuron network architecture.

Virtual Screening of Molecules via Neural Fingerprint-based Deep Learning Technique

Deep Learning in Virtual Screening: Recent Applications and Developments

Machine Learning-Enabled Pipeline for Large-Scale Virtual Drug Screening

Machine learning accelerates pharmacophore-based virtual screening of MAO inhibitors

Deep Learning and Virtual Drug Screening

Improved Scaffold Hopping in Ligand-based Virtual Screening Using Neural Representation Learning

Convolutional Neural Network Based Virtual Screening.

Convolutional Neural Network-based Virtual Screening

Consensus holistic virtual screening for drug discovery: a novel machine learning model approach

Stochastic-based Neural Network hardware acceleration for an efficient ligand-based virtual screening

Novel Big Data-Driven Machine Learning Models for Drug Discovery Application

DENVIS: Scalable and High-Throughput Virtual Screening Using Graph Neural Networks with Atomic and Surface Protein Pocket Features

Novel prediction methods for virtual drug screening

Drug Screening Methods Based on Deep Learning

EMBER-Embedding Multiple Molecular Fingerprints for Virtual Screening

Enhanced Sampling of Chemical Space for High Throughput Screening Applications using Machine Learning

Evaluation of network architecture and data augmentation methods for deep learning in chemogenomics

Deep Scoring Neural Network Replacing the Scoring Function Components to Improve the Performance of Structure-Based Molecular Docking.

Generating and screening de novo compounds against given targets using ultrafast deep learning models as core components

An artificial intelligence accelerated virtual screening platform for drug discovery